Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is a single-site, open-label, phase II trial of C7, a food supplement or medical food,
for the development of treatment outcome measures for glucose transporter type I deficiency
(G1D). The primary outcome measures are: 1. Safety and tolerability of C7 as measured by
changes in comprehensive blood work, including lipid and free fatty acid panels,
self-reported side effects and clinical exam; 2. Changes in brain metabolic rate by MRI and
EEG measurements during C7 treatment; and 3. Maintenance of ketosis in G1D patients on
ketogenic diet, as measured by serial ketone levels during treatment initiation.